
The dangerously blurry line between wellness and medical tech
Let me catch you up. On July 15th, the Food and Drug Administration (FDA) sent Whoop a letter. In it, the FDA declared that Whoop — maker of a niche fitness tracker favored by elite athletes — had crossed a line. Its new Blood Pressure Insights feature, the regulator said, was being marketed to customers without undergoing the proper clearance process.
In response, Whoop pulled out the W word: wellness.
In the world of health and wearable tech, 'wellness' is sort of like a 'get out of jail free' card. Some advanced health features, like EKGs and atrial fibrillation notifications, require regulatory clearance before consumers can use them. These features could be interpreted as diagnostic in nature or prompt a person to make a medical decision. Others, like step tracking and blood oxygen measurements, don't require FDA oversight at all. They're simply meant to make living a healthy life easier by helping you visualize certain measurable markers. Those features fall under the wellness umbrella. They're 'just for fun.'
Whoop's Blood Pressure Insights feature, however, lies in murkier territory.
The way Whoop's feature works is that a user takes readings with a regular blood pressure cuff for calibration. Once that process is complete, Whoop says its tracker uses metrics like 'heart rate, heart rate variability, and blood flow patterns during sleep' to give an estimate of a person's systolic and diastolic blood pressure each morning. The FDA contends that 'providing blood pressure estimation is not a low-risk function' and that a blood pressure estimate inherently implies you're diagnosing hypo- or hypertension. In a statement, Whoop says it 'respectfully disagree[s]' and that this particular feature is more akin to tracking your sleeping respiratory rate. Under the wellness umbrella, Whoop argues it's able to bring an innovative feature to the masses more quickly.
Whoop and the FDA both have points. It's not a stretch to think that a user may get a few 'high' blood pressure estimates, assume they have high blood pressure, and make health decisions informed by that assumption. At the same time, it's clearly labeled as a beta feature, and similar 'diagnostic adjacent' features are available without FDA regulation. I've lost count of how many sleep trackers claim to track 'breathing disturbances.' That may not be explicitly marketed as a sleep apnea detection metric (that would require FDA clearance), but that's semantics. The obvious reason to include it is to flag when a person might want to check themselves for sleep apnea.
The crux of it all is identifying high- and low-risk features for causing harm. Many cases are clear-cut. Natural Cycles, for example, is a period tracking app that claims you can use it as digital contraception using temperature data from wearables like the Oura Ring. It's obvious that a regulatory body should vet a high-stakes feature like that. On the flip side, Samsung's new Antioxidant Index feature for its Galaxy Watch 8 is a silly metric that tells you whether you've eaten enough fruits and veggies. Even if it's inaccurate as hell (I was able to fool it by scanning a Cheez-It), it's not likely to harm your health.
Where the FDA's current process falls short is the increasing number of features that lie somewhere in the middle. Take the Oura Ring. A friend just asked me whether they should get one based on a TikTok video. In said video, celebrity DJ Dillon Francis says the main reason he has an Oura Ring is because it predicts when he's getting sick. This is the Symptom Radar feature, which, in simple terms, flags when you might be getting sick — and it's based on real clinical research conducted during the COVID-19 pandemic. It sounds diagnostic, which requires FDA clearance. But it's not. It's considered a wellness feature because it doesn't tell you what you're falling ill with — just that you might be showing 'early signs of a health change.' And while there's a distinct difference between a diagnosis and a heads-up, it can feel awfully similar to a layperson.
Also, Whoop isn't the only company exploring blood pressure tech. Samsung has a similar feature that's unavailable in the US, as it hasn't been cleared by the FDA. According to Bloomberg, Apple has also been working on an Apple Watch feature that flags when your blood pressure spikes above your baseline, but it reportedly won't spit out direct readings like a continuous glucose monitor would — possibly to avoid FDA clearance as a 'wellness' feature.
Perhaps that means it's time we acknowledge that wellness isn't an innocuous word anymore.
Beyond blood pressure, Samsung and Apple are also widely rumored to be working on blood glucose monitoring features, where the stakes for diabetics could be sky-high. If or when those features do become available, it's possible that companies will adjust how they work to more broadly fit under a wellness label. For instance, instead of glucose readings, you get a trend line or score. I'm skeptical of the average person being able to discern the nuance when even seasoned tech journalists sometimes struggle with the correct verbiage.
Maybe it seems silly to sound the alarm over semantics. But as politicians advocate for greater wearable adoption, the stakes have never been higher. In a better, ideal world, companies would abolish phrases like 'clinically proven' or 'medical grade' from marketing. The FDA would figure out a clearer framework for the design of a wellness feature versus a medical one. But we don't live in an ideal world — and that means it's up to the consumer to know the difference. Frankly, that's not going so well. Perhaps that means it's time we acknowledge that wellness isn't an innocuous word anymore.
Posts from this author will be added to your daily email digest and your homepage feed.
See All by Victoria Song
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Analysis
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Features
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Fitness
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Gadgets
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Health
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Science
Posts from this topic will be added to your daily email digest and your homepage feed.
See All Wearable

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Boston Scientific Stock Outlook: Is Wall Street Bullish or Bearish?
Boston Scientific Corporation (BSX), headquartered in Marlborough, Massachusetts, develops, manufactures, and markets medical devices for use in various interventional medical specialties globally. With a market cap of $157.9 billion, the company's products are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, and more. Shares of this medTech giant have outperformed the broader market over the past year. BSX has gained 41.7% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 16.6%. In 2025, BSX stock is up 17.5%, surpassing the SPX's 7.8% rise on a YTD basis. More News from Barchart With UnitedHealth Under DOJ Investigation, Should You Buy, Sell, or Hold UNH Stock Now? Trump Won't Take Away Tesla's Subsidies. Does That Make TSLA Stock a Safe Buy Here? Can AMD Stock Hit $210 in 2025? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Zooming in further, BSX's outperformance is also apparent compared to the iShares U.S. Medical Devices ETF (IHI). The exchange-traded fund has gained about 9% over the past year. Moreover, BSX's double-digit gains on a YTD basis outshine the ETF's 2.3% gains over the same time frame. BSX's strong performance can be credited to its robust product portfolio and dedicated global team. Key achievements in the second quarter include FDA approval for expanding the FARAPULSE PFA System, initiation of the ReMATCH IDE trial, and securing CE Mark for the WATCHMAN FLX Pro device in Europe. The company also finalized the acquisitions of Intera Oncology and SoniVie, enhancing its offerings in liver cancer and hypertension treatment technologies. On Jul. 23, BSX shares closed up more than 4% after reporting its Q2 results. Its adjusted EPS of $0.75 beat Wall Street's expectations of $0.72. The company's revenue was $5.1 billion, exceeding Wall Street forecasts of $4.9 billion. The company expects full-year adjusted EPS in the range of $2.95 to $2.99. For the current fiscal year, ending in December, analysts expect BSX's EPS to grow 18.7% to $2.98 on a diluted basis. The company's earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters. Among the 30 analysts covering BSX stock, the consensus is a 'Strong Buy.' That's based on 27 'Strong Buy' ratings, two 'Moderate Buys,' and one 'Hold.' This configuration is more bullish than two months ago, with 26 analysts suggesting a 'Strong Buy.' On Jul. 24, Raymond James Financial, Inc. (RJF) analyst Jayson Bedford maintained a 'Buy' rating on BSX with a price target of $124, implying a potential upside of 18.2% from current levels. The mean price target of $124.53 represents an 18.7% premium to BSX's current price levels. The Street-high price target of $140 suggests an ambitious upside potential of 33.4%. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
5 hours ago
- Yahoo
DOJ reaches $9.8 million settlement with Illumina over cyber whistleblower claims
This story was originally published on Cybersecurity Dive. To receive daily news and insights, subscribe to our free daily Cybersecurity Dive newsletter. The Department of Justice on Thursday announced a $9.8 million settlement with Illumina over allegations that the company sold genomic-sequencing systems with software vulnerabilities to federal agencies for multiple years. Between 2016 and 2023, the government said, the company sold the systems without having an adequate security program and knowingly failed to incorporate cybersecurity into its product design process. According to prosecutors' complaint, Illumina is the dominant company in the global market, with a share of roughly 80%. 'Companies that sell products to the federal government will be held accountable for failing to adhere to cybersecurity standards and protecting against cybersecurity risks,' Assistant Attorney General Brett Shumate of the DOJ's Civil Division said in a statement. 'This settlement underscores the importance of cybersecurity in handling genetic information and the department's commitment to ensuring that federal contractors adhere to requirements to protect sensitive information from cyber threats,' he added. Illumina denied the allegations that it knowingly sold defective products, and the agreement states that the company is not making any admissions related to those claims. The Food and Drug Administration in 2023 issued a warning about a vulnerability in Illumina software that could allow an attacker to change settings on the device or even take it over remotely. In 2022, the Cybersecurity and Infrastructure Security Agency warned about a flaw in Illumina's Local Run Manager software that could allow an attacker to remotely alter test results. The company later patched the flaw. The case involved a whistleblower — Erica Lenore, a former director of platform management at Illumina — who provided the government with details about the company's alleged noncompliance. Lenore will receive $1.9 million from the settlement. Illumina said while it disagrees with the allegations from the government, it decided to settle the matter due to the 'uncertainty, expense and distraction' of litigating the case. The company noted the claims related to software issues, which Illumina says it successfully remediated from 2022 to 2024. 'Government agencies, including the U.S. Food and Drug Administration (FDA), are important customers and Illumina values these relationships,' the company said in a statement. 'Illumina takes data security seriously and has invested significantly in its programs to align with cybersecurity best practices for the development and deployment of our products. DOJ also reached a $1.75 million settlement with defense contractor Aero Turbine Inc. and private equity firm Galant Capital Partners, over claims they failed to meet cybersecurity standards related to an Air Force contract. The DOJ did credit them for voluntarily coming forward to cooperate in the case. (Updates with comments from company) Recommended Reading US government plays catchup on phishing-resistant MFA Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Immunitybio (IBRX) Targets $80 Million Capital Raise for Business Operations
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the penny stocks that will skyrocket. On July 25, the company confirmed it is eyeing $80 million in gross proceeds on the execution of a securities purchase agreement as part of a registered direct offering. It also plans to issue common stock and warrants for the purchase of additional shares. M. A. Arkhipov/ Once fully exercised, the warrants could yield up to $96 million in gross proceeds. Piper Sandler and Co. is acting as the placement agent of the registered direct offering. The net proceeds from the offering are expected to provide the company with much-needed working capital and support for its ongoing business operations. The direct offering comes on the company's ANKTIVA product, receiving FDA approval as an immunotherapy for non-muscle invasive bladder cancer. The flagship product is designated for FDA Breakthrough Therapy. ImmunityBio, Inc. (NASDAQ:IBRX) is a biotechnology company focused on developing next-generation immunotherapies and vaccines that harness the power of the immune system to fight cancer and infectious diseases. It seeks to create durable and safe protection against diseases by developing innovative therapies and cell therapies that bolster the natural immune response. While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and 11 Defensive Stocks Billionaires are Buying amid US Trade Tariff Uncertainty. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data